Axio BioPharma is a CDMO using AI to accelerate the development of mammalian-expressed recombinant proteins.
Axio BioPharma has raised $515K in total funding. The most recent round was Seed. The last funding was announced in January 2025.
Axio BioPharma's investors include Chisos Capital, Chemical Angel Network.
Axio BioPharma is headquartered in Madison, United States.
Axio BioPharma is a CDMO using AI to accelerate the development of mammalian-expressed recombinant proteins.
Axio BioPharma is at the Seed stage.
Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated .
"Axio BioPharma — Funding & Investors." VCBacked, January 1, 2025, https://www.vcbacked.co/company/axio-biopharma. Accessed September 15, 2026.
VCBacked. (2025). Axio BioPharma — Funding & Investors. Retrieved September 15, 2026, from https://www.vcbacked.co/company/axio-biopharma
{{cite web |title=Axio BioPharma — Funding & Investors |url=https://www.vcbacked.co/company/axio-biopharma |website=VCBacked |access-date=September 15, 2026}}Profile data sourced and verified per the VCbacked methodology · Last funding round dated